Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Dementia venture fund raises $350 million to hunt new drugs

LONDON (Reuters) - A venture capital fund dedicated to finding new ways to prevent and treat dementia has raised $350 million, far exceeding the initial target of $200 million set on its launch in 2015.

The global Dementia Discovery Fund (DDF), an initiative of former British prime minister David Cameron, brings together government, industry and charities.

The total, announced on Monday, was reached following a $60 million investment by AARP, the U.S. non-profit group representing Americans over the age of 50, plus new cash from companies including UnitedHealth, Aegon and Quest Diagnostics.

Other existing backers include billionaire Microsoft co-founder Bill Gates and several drug companies, including GlaxoSmithKline, Johnson & Johnson and Eli Lilly, as well as the UK government.

Venture capital funds are a common source of finance for high-risk, early-stage life science research, but the new fund is the first to focus solely on dementia.

The DDF has built an initial portfolio of 16 investments in biotech companies, mainly in Britain and the United States. It aims to study potential therapies beyond the prevailing “amyloid beta hypothesis” - the idea that Alzheimer’s can be tackled by blocking the build-up of plaque in the brain.

The fund also said former Celgene business development head Angus Grant would be its new chief executive.

There is still no treatment that can slow the progression of Alzheimer’s, the commonest form of dementia. Current drugs can do no more than ease some of the symptoms.

JUNE 25, 2018


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies